Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where David Aaron Schwartz is active.

Publication


Featured researches published by David Aaron Schwartz.


Journal of Autoimmunity | 1990

Induction of non-specific suppressor cells in normal Lewis rats by a novel azaspirane SK&F 105685.

Alison M. Badger; Andrew G. King; James E. Talmadge; David Aaron Schwartz; Donald H. Picker; Christopher K. Mirabelli; Nabil Hanna

SK&F 105685 (N,N-Dimethyl-8,8-dipropyl-2-azaspiro[4,5]decane-2- propanamine dihydrochloride) is a novel azaspirane which has therapeutic activity in rat models of autoimmune disease. In this study, we have demonstrated that SK&F 105685 is a potent inducer of non-specific suppressor cells (SC). Oral administration of 15-30 mg/kg/day results in the generation of SC in the spleen, lymph nodes and bone marrow, but not the thymus of Lewis rats. Splenic SC suppress Con-A-induced proliferation in co-culture assays at effector-responder ratios of 1:1 to 1:64. SC are radiation resistant (2000 R), non-T, non-B cells, partially adherent to plastic surfaces and are enriched in a 1.07 g/ml fraction of a Percoll density gradient. Their activity is increased, rather than ablated, by indomethacin. No definitive changes in Ig+, OX-19+, OX-8+, W3/25+ or asialo GM1+ cells could be detected in the spleens of treated rats compared to control untreated animals. Elevated levels of both radiation-sensitive and radiation-resistant suppressor cells were found in the bone marrow of treated rats in addition to the radiosensitive SC normally present in this tissue.


Bioconjugate Chemistry | 1991

Preparation of hydrazino-modified proteins and their use for the synthesis of 99mTc-protein conjugates

David Aaron Schwartz; Michael J. Abrams; Marguerite M. Hauser; Forrest E. Gaul; Scott K. Larsen; Donald Rauh; Jon Zubieta


Archive | 1989

Antiviral cyclic polyamines

Barry A. Murrer; David Aaron Schwartz


Archive | 1988

Macromolecular platinum antitumor compounds

Anthony Serino; Geoffrey W. Henson; David Aaron Schwartz; Donald H. Picker


Journal of Medicinal Chemistry | 1990

Antiarthritic and supressor cell inducing activity of azaspiranes: structure-function relationships of a novel class of immunomodulatory agents

Alison M. Badger; David Aaron Schwartz; Donald H. Picker; James Woodrow Dorman; Fontaine C. Bradley; Elaine Nicholas Cheeseman; Michael J. DiMartino; Nabil Hanna; Christopher K. Mirabelli


Inorganica Chimica Acta | 1987

A convenient preparation of the amminetrichloroplatinate(II) anion

Michael J. Abrams; Christen M. Giandomenico; Jean F. Vollano; David Aaron Schwartz


Archive | 1992

Certain pyridyl hydrazines and hydrazides useful for protein labeling

David Aaron Schwartz; Michael J. Abrams; Christen M. Giadomenico; Jon A. Zubieta


The Journal of Nuclear Medicine | 1997

Tumor Imaging with Technetium-99m-Labeled Hydrazinonicotinamide-Fab′ Conjugates

Michiel E. Ultee; Gary J. Bridger; Michael J. Abrams; Clifford B. Longley; Charlotte A. Burton; Scott Kenneth Larsen; Geoffrey W. Henson; Sreenivasan Padmanabhan; Forrest E. Gaul; David Aaron Schwartz


Archive | 1993

Molecule labelling using 2-hydraninopyridine derivatives

Michael J. Abrams; Gary J. Bridger; David Aaron Schwartz; Sreenivasan Padmanabhan; Michael Evert Ultee


Bioconjugate Chemistry | 1996

A comparison of cleavable and noncleavable hydrazinopyridine linkers for the 99mTc labeling of Fab' monoclonal antibody fragments.

Gary J. Bridger; Michael J. Abrams; Sreenivasan Padmanabhan; Forrest E. Gaul; Scott Kenneth Larsen; Geoffrey W. Henson; David Aaron Schwartz; Clifford B. Longley; Charlotte A. Burton; Michiel E. Ultee

Collaboration


Dive into the David Aaron Schwartz's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge